360 degree trabeculectomy best way to treat congenital glaucoma

Article

Using a microcatheter to perform 360° trabeculectomy is a safer and more consistent way to treat congenital glaucoma than traditional trabeculectomy, according to information presented at this year's meeting of the American Glaucoma Society (AGS).

Using a microcatheter to perform 360º trabeculectomy is a safer and more consistent way to treat congenital glaucoma than traditional trabeculectomy, according to information presented at this year's meeting of the American Glaucoma Society (AGS).

Adam C. Reynolds, MD of the Dean McGee Eye Institute, University of Oklahoma, US and colleagues performed 360º trabeculectomy using the iTrack catheter (iScience Interventional), a laser guided microcatheter designed to pass 360º through Schlemm's canal, in 12 congenital glaucoma eyes (nine patients) where trabeculectomy or goniotomy would have been the traditional surgical approach. Mean IOP of preoperative eyes was 31 mmHg.

In 75% of treated eyes (n=8), 360º trabeculectomy from a single surgical site was performed successfully. Of the remaining eyes, 50% (n=2) had previously undergone goniotomies, but most of the remaining angle (for a minimum of 200º) was cannulated using this method.

After 6.6 months, two eyes had required shunts to be placed. Although the follow-up period was too short to gauge postoperative visual outcomes, corneal clarity has improved and medical therapy been discontinued in the majority of cases. Mean IOP, postoperatively, was 17 mmHg.

The surgeons concluded that this method of treating congenital glaucoma is effective and offers a lower risk of surgical complications, although the follow-up period was too short to make any definitive assessment of long-term outcomes when compared with traditional methods.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.